Forest Laboratories, Inc. (NYSE:FRX) and Almirall, S.A. (ALM:MC) today announced positive topline results from AUGMENT COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA), delivered in the Pressair® (Genuair® outside the USA) inhaler.

The 400/12mcg combination of aclidinium/formoterol demonstrated statistically significant improvements in change from baseline for the co-primary endpoints of Forced Expiratory Volume (FEV1) at 1 hour post-dose versus aclidinium 400mcg (P

Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Forest Road Acquisition Charts.
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Forest Road Acquisition Charts.